Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes
Journal
The Journal of Clinical Endocrinology and Metabolism
Date Issued
2007-08
Author(s)
Pörksen, Sven
Nielsen, Lotte B
Kaas, Anne
Chiarelli, Francesco
Orskov, Cathrine
Holst, Jens J
Ploug, Kenneth B
Hougaard, Philip
Hansen, Lars
Mortensen, Henrik B
DOI
10.1210/jc.2007-0244
Abstract
Context: The role of glucagon in hyperglycemia in type 1 diabetes is unresolved, and in vitro studies suggest that increasing blood glucose might stimulate glucagon secretion.
Objective: Our objective was to investigate the relationship between postprandial glucose and glucagon level during the first 12 months after diagnosis of childhood type 1 diabetes.
Design: We conducted a prospective, noninterventional, 12-month follow-up study conducted in 22 centers in 18 countries.
Patients: Patients included 257 children and adolescents less than 16 yr old with newly diagnosed type 1 diabetes; 204 completed the 12-month follow-up.
Setting: The study was conduced at pediatric outpatient clinics.
Main Outcome Measures: We assessed residual β-cell function (C-peptide), glycosylated hemoglobin (HbA1c), blood glucose, glucagon, and glucagon-like peptide-1 (GLP-1) release in response to a 90-min meal stimulation (Boost) at 1, 6, and 12 months after diagnosis.
Results: Compound symmetric repeated-measurements models including all three visits showed that postprandial glucagon increased by 17% during follow-up (P = 0.001). Glucagon levels were highly associated with postprandial blood glucose levels because a 10 mmol/liter increase in blood glucose corresponded to a 20% increase in glucagon release (P = 0.0003). Glucagon levels were also associated with GLP-1 release because a 10% increase in GLP-1 corresponded to a 2% increase in glucagon release (P = 0.0003). Glucagon levels were not associated (coefficient −0.21, P = 0.07) with HbA1c, adjusted for insulin dose. Immunohistochemical staining confirmed the presence of Kir6.2/SUR1 in human α-cells.
Conclusion: Our study supports the recent in vitro data showing a stimulation of glucagon secretion by high glucose levels. Postprandial glucagon levels were not associated with HbA1c, adjusted for insulin dose, during the first year after onset of childhood type 1 diabetes.
Objective: Our objective was to investigate the relationship between postprandial glucose and glucagon level during the first 12 months after diagnosis of childhood type 1 diabetes.
Design: We conducted a prospective, noninterventional, 12-month follow-up study conducted in 22 centers in 18 countries.
Patients: Patients included 257 children and adolescents less than 16 yr old with newly diagnosed type 1 diabetes; 204 completed the 12-month follow-up.
Setting: The study was conduced at pediatric outpatient clinics.
Main Outcome Measures: We assessed residual β-cell function (C-peptide), glycosylated hemoglobin (HbA1c), blood glucose, glucagon, and glucagon-like peptide-1 (GLP-1) release in response to a 90-min meal stimulation (Boost) at 1, 6, and 12 months after diagnosis.
Results: Compound symmetric repeated-measurements models including all three visits showed that postprandial glucagon increased by 17% during follow-up (P = 0.001). Glucagon levels were highly associated with postprandial blood glucose levels because a 10 mmol/liter increase in blood glucose corresponded to a 20% increase in glucagon release (P = 0.0003). Glucagon levels were also associated with GLP-1 release because a 10% increase in GLP-1 corresponded to a 2% increase in glucagon release (P = 0.0003). Glucagon levels were not associated (coefficient −0.21, P = 0.07) with HbA1c, adjusted for insulin dose. Immunohistochemical staining confirmed the presence of Kir6.2/SUR1 in human α-cells.
Conclusion: Our study supports the recent in vitro data showing a stimulation of glucagon secretion by high glucose levels. Postprandial glucagon levels were not associated with HbA1c, adjusted for insulin dose, during the first year after onset of childhood type 1 diabetes.